GlaxoSmithKline has stopped a high-profile clinical trial using a novel vaccine to fight lung cancer after deciding it will not be possible to find a sub-group of patients who might benefit. The decision comes less than two weeks after the British drugmaker said the MAGE-A3 therapeutic vaccine did not help patients with non-small cell lung cancer in the Phase III study but that it planned to continue to trial in the hope of identifying patients with a particular genetic profile for whom it would work.
via Health News Headlines - Yahoo News http://ift.tt/1s6fW1M
No comments:
Post a Comment